Reporting positive treatment outcomes with bendamustine + rituximab in indolent lymphomas
Why daratumumab will become key for the treatment of multiple myeloma
Harnessing T-cells in acute leukemia and an anti-CD33/CD3 BiTE antibody
What’s new in minimal residual disease (MRD) detection in myeloma?
Overview of the SIRIUS clinical trial in the treatment of multiple myeloma